Pfizer Inc. (PFE)’s strategy to keep its market share of cholesterol pill Lipitor may boost revenue without aiding profit, said the chief executive officer of Watson Pharmaceuticals Inc. (WPI), the drugmaker’s partner on the medicine’s generic version. Pfizer’s plan to hold off generic competition may be failing, said Paul Bisaro, Watson’s CEO. Pfizer, the world’s largest drugmaker, gave Parsippany, New Jersey-based Watson the right to sell an “authorized” copy of Lipitor for a share of the revenue generated by the generic drug. “They’re starting to lose market share,” Bisaro said today at a company meeting with analysts. “It appeared they were trying to protect revenue and not profit,” he said.
